Sofosbuvir/Ledipasvir for Treatment of Chronic Hepatitis C Infection in Adult Patients with β- Thalassemia Major: A Real-Life Study
| Autor: | Yousry Esam-Eldin Abo-Amer, Sherief Abd-Elsalam, Amina Fouad, Sahar Mohamed Mostafa, Tamer A Elbedewy, Raghda Samir Abdellatif, Mona Youssef, Mohamed A Elsebaey |
|---|---|
| Rok vydání: | 2020 |
| Předmět: |
Ledipasvir
Adult medicine.medical_specialty Blood transfusion Sofosbuvir Genotype Endocrinology Diabetes and Metabolism Hepatitis C virus Thalassemia medicine.medical_treatment Fixed-dose combination Chronic liver disease medicine.disease_cause Gastroenterology Antiviral Agents chemistry.chemical_compound Internal medicine Immunology and Allergy Medicine Humans Retrospective Studies Fluorenes business.industry beta-Thalassemia Hepatitis C Chronic medicine.disease Regimen Treatment Outcome chemistry Benzimidazoles Drug Therapy Combination business Uridine Monophosphate medicine.drug |
| Zdroj: | Endocrine, metabolicimmune disorders drug targets. 22(3) |
| ISSN: | 2212-3873 |
| Popis: | Background & Aims: Patients with thalassemia have a lifelong need for blood transfusion, which makes them more risky to hepatitis C virus (HCV). Iron overload and chronic HCV are considered risk factors for patients with thalassemia to develop liver insults. The aim of the present study is to investigate the safety and efficacy of sofosbuvir/ledipasvir in the treatment of chronic HCV infection in Egyptian adult patients with β- thalassemia major. Methods: A retrospective study included 53 patients with β-thalassemia major with chronic HCV treated with sofosbuvir (400 mg) and ledipasvir (90 mg) as a single pill fixed-dose combination once daily for 12 weeks. The effectiveness of the treatment was assessed by the sustained virologic response (SVR) at 12 weeks after the end of the treatment. Results: SVR was achieved in 96.23% of patients. 47.17% of patients had minor side effects. There was a significant reduction in ALT, AST, and serum ferritin 12 weeks post-therapy. There was an insignificant change in hemoglobin level or blood transfusion requirement 12 weeks posttherapy. There was no change in iron chelators doses throughout the study period. Conclusion: Sofosbuvir/ledipasvir regimen seems to be safe and highly effective in the treatment of chronic HCV in patients with β-thalassemia major. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|